Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Telaprevir Simmering, Flush Vertex Raises $320 Million More

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm moves away from “science-based” buyers and herds three institutional, longer-view backers into a single public offering.

You may also be interested in...



Vertex's Latest Finance Play: Selling Off EU Milestone Payments For Telaprevir

Curious announcement could presage a deal already in place or be an effort to draw competing bids.

Vertex's Latest Finance Play: Selling Off EU Milestone Payments For Telaprevir

Curious announcement could presage a deal already in place or be an effort to draw competing bids.

For U.S. Biotechs, Money Is Available Again But It Doesn’t Come Cheap

Oncothyreon is typical of many small publicly traded biotechs these days: the Seattle-based biotech finished the first quarter of 2009 with just $15.4 million in cash and equivalents, necessitating a careful husbanding of finances. But because it's been enjoying a recent uptick in market cap, the oncology-focused biotech raised $11.1 million via a registered direct offering

Related Content

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel